News from map pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 02, 2013, 17:15 ET

MAP Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 31st Annual J.P. Morgan Healthcare Conference on...

Nov 21, 2012, 17:00 ET

MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX®

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that its New Drug Application (NDA) resubmission for LEVADEX® orally inhaled migraine...

Nov 08, 2012, 16:30 ET

MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following investor conferences: Lazard Capital...

Nov 01, 2012, 16:10 ET

MAP Pharmaceuticals Reports Third Quarter of 2012 Financial Results

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2012. The net loss...

Oct 16, 2012, 07:00 ET

MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has resubmitted its New Drug Application (NDA) to the United States Food...

Aug 29, 2012, 17:00 ET

MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the underwriter of its recent public offering of common stock fully exercised...

Aug 09, 2012, 07:00 ET

MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following investor conferences: Canaccord Genuity...

Aug 01, 2012, 09:05 ET

MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the pricing of an underwritten public offering of 3,880,598 shares of its common...

Jul 31, 2012, 16:02 ET

MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it intends to offer and sell shares of its common stock in an underwritten...

Jul 24, 2012, 07:00 ET

MAP Pharmaceuticals Reports Second Quarter of 2012 Financial Results

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2012. The net loss for the...

Jun 25, 2012, 07:00 ET

MAP Pharmaceuticals Provides Update Following Meeting with FDA for LEVADEX® (dihydroergotamine) New Drug Application

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company completed an End-of-Review meeting with the United States Food and Drug...

Jun 21, 2012, 16:05 ET

MAP Pharmaceuticals to Present Data on LEVADEX® at the 54th Annual Scientific Meeting of the American Headache Society

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present data on LEVADEX® (formerly MAP0004), an orally inhaled...

May 04, 2012, 07:00 ET

MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2012. The net loss for the first...

May 01, 2012, 07:00 ET

MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in May...

Apr 12, 2012, 16:05 ET

MAP Pharmaceuticals Provides Update on LEVADEX® Program

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on LEVADEX®, the Company's investigational orally inhaled drug for the...

Mar 29, 2012, 07:00 ET

MAP Pharmaceuticals Reports 2011 Fourth Quarter and Year End Financial Results

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2011. The net...

Mar 26, 2012, 19:23 ET

MAP Pharmaceuticals Receives Complete Response Letter from FDA for LEVADEX® (dihydroergotamine) NDA

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Food and Drug Administration (FDA) has issued a Complete...

Feb 23, 2012, 07:00 ET

MAP Pharmaceuticals Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company U.S....

Feb 08, 2012, 07:00 ET

MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in...

Jan 17, 2012, 07:00 ET

MAP Pharmaceuticals Appoints W. James O'Shea to Board of Directors

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of W. James O'Shea to its Board of Directors. Mr. O'Shea brings to...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge